Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2010

01-12-2010 | Original Article

High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease

Authors: Hyun Ju Kim, Nosratola D. Vaziri, Keith Norris, Won Suk An, Yasmir Quiroz, Bernardo Rodriguez-Iturbe

Published in: Clinical and Experimental Nephrology | Issue 6/2010

Login to get access

Abstract

Background

In earlier studies we found that a high-fat, high-energy diet (HFED) attenuates proteinuria, azotemia and lipid accumulation in the remnant kidney of rats subjected to 5/6 nephrectomy. This study was conducted to explore the mechanism of the salutary effect of HFED in association with moderate protein restriction in this model.

Methods

The 5/6 nephrectomized male rats were randomized to receive regular rat chow (CRF group, n = 6) or HFED diet (CRF + HFED, n = 7) for 12 weeks. Sham-operated rats served as controls (n = 6).

Results

The CRF group exhibited azotemia, hypertension, proteinuria, diminished body weight, oxidative stress, glomerulosclerosis, tubulo-interstitial inflammation and upregulation of pro-oxidant [NAD(P)H oxidase], pro-inflammatory (NF-κB activation, increased MCP-1, lipoxygenase, ICAM-1, VCAM-1), pro-fibrotic (TGF-β, CTGF) and pro-apoptotic pathways (Bax, caspase-3) in the remnant kidney. Consumption of the HFED resulted in a 66% increment in lipid intake, 8% increment in carbohydrate intake and a 24% reduction in protein intake. The CRF + HFED group gained weight normally, had increments in leptin and adiponectin levels, and despite increments in plasma cholesterol and fatty acids, showed significant attenuation of oxidative stress, proteinuria and inflammation, and partial reversal of the remnant kidney upregulation of pro-oxidant, pro-inflammatory, pro-fibrotic and pro-apoptotic pathways.

Conclusion

Consumption of high-energy diet in association with mild protein restriction results in suppression of upregulated pathways that drive progression of renal injury in the remnant kidney model. These findings may have relevance in the management of chronic kidney disease in humans.
Literature
1.
go back to reference Degoulet P, Legrain M, Réach I, Aimé F, Devriés C, Rojas P, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982;31:103–10.CrossRefPubMed Degoulet P, Legrain M, Réach I, Aimé F, Devriés C, Rojas P, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982;31:103–10.CrossRefPubMed
2.
go back to reference Leavy SD, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 1998;31:997–1006.CrossRef Leavy SD, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 1998;31:997–1006.CrossRef
3.
go back to reference Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in hemodialysis patients. Kidney Int. 1999;56:1136–48.CrossRefPubMed Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in hemodialysis patients. Kidney Int. 1999;56:1136–48.CrossRefPubMed
4.
go back to reference Fleishmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 1999;55:1560–7.CrossRef Fleishmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 1999;55:1560–7.CrossRef
5.
go back to reference Leavy SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in “healthier” as compared with “sicker” hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386–94.CrossRef Leavy SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in “healthier” as compared with “sicker” hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386–94.CrossRef
6.
go back to reference Glanton CW, Hypolite IO, Hshieh PB, Agoada LY, Yuan CM, Abott KC. Factors associated with short term survival in obese end stage renal disease patients. Ann Epidemiol. 2003;13:136–43.CrossRefPubMed Glanton CW, Hypolite IO, Hshieh PB, Agoada LY, Yuan CM, Abott KC. Factors associated with short term survival in obese end stage renal disease patients. Ann Epidemiol. 2003;13:136–43.CrossRefPubMed
7.
go back to reference Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003;42:761–73.CrossRefPubMed Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003;42:761–73.CrossRefPubMed
8.
go back to reference Abbott KC, Glanton CW, Trespalacios FC, Oliver DK, Ortiz MI, Agodoa LY, et al. Body mass index, dialysis modality and survival: analysis of the United States Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004;65:597–605.CrossRefPubMed Abbott KC, Glanton CW, Trespalacios FC, Oliver DK, Ortiz MI, Agodoa LY, et al. Body mass index, dialysis modality and survival: analysis of the United States Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004;65:597–605.CrossRefPubMed
9.
go back to reference Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16–23.PubMed Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16–23.PubMed
10.
go back to reference Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561–9.CrossRefPubMed Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561–9.CrossRefPubMed
11.
go back to reference Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis. 2001;38:S4–7.CrossRefPubMed Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis. 2001;38:S4–7.CrossRefPubMed
12.
go back to reference Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004;15:442–52.CrossRefPubMed Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004;15:442–52.CrossRefPubMed
13.
go back to reference Lowrie EJ, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an elevation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–82.PubMed Lowrie EJ, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an elevation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–82.PubMed
14.
go back to reference Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular disease risk factors in maintenance dialysis. Kidney Int. 2003;63:793–808.CrossRefPubMed Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular disease risk factors in maintenance dialysis. Kidney Int. 2003;63:793–808.CrossRefPubMed
15.
go back to reference Rodriguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int. 2005;68:1041–7.CrossRefPubMed Rodriguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int. 2005;68:1041–7.CrossRefPubMed
16.
go back to reference Reddy S, Santanam N, Reddy PP, Rock JA, Murphy AA, Parthasarathy S. Interaction of interceed oxidized regenerated cellulose with macrophages: a potential mechanism by which interceed may prevent adhesions. Am J Obstet Gynecol. 1997;177:1315–20.CrossRefPubMed Reddy S, Santanam N, Reddy PP, Rock JA, Murphy AA, Parthasarathy S. Interaction of interceed oxidized regenerated cellulose with macrophages: a potential mechanism by which interceed may prevent adhesions. Am J Obstet Gynecol. 1997;177:1315–20.CrossRefPubMed
17.
go back to reference Chade AR, Mushin OP, Zhu X, Rodriguez-Porcel M, Grande JP, Textor SC, et al. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005;46:772–9.CrossRefPubMed Chade AR, Mushin OP, Zhu X, Rodriguez-Porcel M, Grande JP, Textor SC, et al. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005;46:772–9.CrossRefPubMed
18.
go back to reference Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int. 1999;56:440–51.CrossRefPubMed Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int. 1999;56:440–51.CrossRefPubMed
19.
go back to reference Okamura DM, Lopez-Guisa JM, Koelsch K, Collins S, Eddy AA. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol. 2007;293:F575–85.CrossRefPubMed Okamura DM, Lopez-Guisa JM, Koelsch K, Collins S, Eddy AA. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol. 2007;293:F575–85.CrossRefPubMed
21.
go back to reference Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010;298:F662–71.CrossRefPubMed Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010;298:F662–71.CrossRefPubMed
22.
go back to reference Alvarez V, Quiroz Y, Nava M, Pons H, Rodriguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol. 2002;283:F1132–41.PubMed Alvarez V, Quiroz Y, Nava M, Pons H, Rodriguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol. 2002;283:F1132–41.PubMed
23.
go back to reference Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of Nuclear Factor kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315:51–7.CrossRefPubMed Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of Nuclear Factor kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315:51–7.CrossRefPubMed
24.
go back to reference Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol. 2008;294:F336–44.CrossRefPubMed Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol. 2008;294:F336–44.CrossRefPubMed
25.
go back to reference Cho K-H, Kim H-J, Rodriguez-Iturbe B, Vaziri ND. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol. 2009;297:F106–13.CrossRefPubMed Cho K-H, Kim H-J, Rodriguez-Iturbe B, Vaziri ND. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol. 2009;297:F106–13.CrossRefPubMed
26.
go back to reference Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol. 2009;112:e31–42.CrossRefPubMed Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol. 2009;112:e31–42.CrossRefPubMed
27.
go back to reference Fouque D, Aparicio M. Eleven reasons to control the protein intake of patients with chronic kidney disease. Nat Clin Pract Nephrol. 2007;3:383–92.CrossRefPubMed Fouque D, Aparicio M. Eleven reasons to control the protein intake of patients with chronic kidney disease. Nat Clin Pract Nephrol. 2007;3:383–92.CrossRefPubMed
28.
go back to reference Vaziri ND. Molecular mechanisms of lipid dysregulation in nephrotic syndrome. Kidney Int. 2003;63:1964–76.CrossRefPubMed Vaziri ND. Molecular mechanisms of lipid dysregulation in nephrotic syndrome. Kidney Int. 2003;63:1964–76.CrossRefPubMed
29.
go back to reference Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J Am Soc Nephrol. 2002;13:134–41.CrossRefPubMed Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J Am Soc Nephrol. 2002;13:134–41.CrossRefPubMed
30.
go back to reference Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum. Kidney Int. 2007;71:1195–7.CrossRefPubMed Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum. Kidney Int. 2007;71:1195–7.CrossRefPubMed
31.
go back to reference Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome––the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.PubMed Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome––the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.PubMed
32.
go back to reference Díez JJ, Iglesias P, Fernández-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol. 2005;62:242–9.CrossRef Díez JJ, Iglesias P, Fernández-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol. 2005;62:242–9.CrossRef
33.
34.
go back to reference Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition and indices of malnutrition in patients in dialysis. J Amer Soc Nephrol. 1998;9:1080–4. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition and indices of malnutrition in patients in dialysis. J Amer Soc Nephrol. 1998;9:1080–4.
35.
go back to reference Aminzadeh MA, Pahl MV, Barton CH, Vaziri ND. Human uremic plasma stimulates release of leptin and uptake of tumor necrosis factor-α in visceral adipocytes. Nephrol Dial Transplant. 2009;24:3626–31.CrossRefPubMed Aminzadeh MA, Pahl MV, Barton CH, Vaziri ND. Human uremic plasma stimulates release of leptin and uptake of tumor necrosis factor-α in visceral adipocytes. Nephrol Dial Transplant. 2009;24:3626–31.CrossRefPubMed
36.
go back to reference Hung S-C, Tung T-Y, Yang C-S, Tarng D-C. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. Am J Kidney Dis. 2005;45:1073–83.CrossRefPubMed Hung S-C, Tung T-Y, Yang C-S, Tarng D-C. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. Am J Kidney Dis. 2005;45:1073–83.CrossRefPubMed
37.
go back to reference Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40:104–9.CrossRefPubMed Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40:104–9.CrossRefPubMed
38.
go back to reference Sinuani I, Weissgarten J, Beberashvili I, Rapoport MJ, Sandbank J, Feldman L, et al. The cyclin kinase inhibitor p57kip2 regulates TGF-β-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101. Nephrol Dial Transplant. 2009;24:2328–38.CrossRefPubMed Sinuani I, Weissgarten J, Beberashvili I, Rapoport MJ, Sandbank J, Feldman L, et al. The cyclin kinase inhibitor p57kip2 regulates TGF-β-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101. Nephrol Dial Transplant. 2009;24:2328–38.CrossRefPubMed
39.
go back to reference Chen M, Narumiya S, Masaki T, Sawamura T. Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding. Biochem J. 2001;355:289–96.CrossRefPubMed Chen M, Narumiya S, Masaki T, Sawamura T. Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding. Biochem J. 2001;355:289–96.CrossRefPubMed
40.
go back to reference Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with NOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens. 2005;23:87–96.CrossRefPubMed Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with NOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens. 2005;23:87–96.CrossRefPubMed
41.
go back to reference Metha JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006;69:36–45.CrossRef Metha JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006;69:36–45.CrossRef
42.
go back to reference Kim HJ, Moradi H, Yuan J, Norris K, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009;296:F1297–306.CrossRefPubMed Kim HJ, Moradi H, Yuan J, Norris K, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009;296:F1297–306.CrossRefPubMed
43.
go back to reference Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol. 2010;31:435–41.CrossRefPubMed Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol. 2010;31:435–41.CrossRefPubMed
44.
go back to reference Sinha-Hikim I, Shen R, Paul Lee WN, Crum A, Vaziri ND, Norris KC. Effects of a novel cystine based glutathione precursor on oxidative stress in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2010. doi:10.1152/ajpcell.00434.2009. Sinha-Hikim I, Shen R, Paul Lee WN, Crum A, Vaziri ND, Norris KC. Effects of a novel cystine based glutathione precursor on oxidative stress in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2010. doi:10.​1152/​ajpcell.​00434.​2009.
45.
go back to reference Igarashi K, Ueda S, Yoshida K, Kashiwagi K. Polyamines in renal failure. Amino Acids. 2006;31:477–83.CrossRefPubMed Igarashi K, Ueda S, Yoshida K, Kashiwagi K. Polyamines in renal failure. Amino Acids. 2006;31:477–83.CrossRefPubMed
Metadata
Title
High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease
Authors
Hyun Ju Kim
Nosratola D. Vaziri
Keith Norris
Won Suk An
Yasmir Quiroz
Bernardo Rodriguez-Iturbe
Publication date
01-12-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0340-x

Other articles of this Issue 6/2010

Clinical and Experimental Nephrology 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine